Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report report published on Wednesday. The firm issued a sell rating on the stock.

Bio-Path Stock Down 1.0 %

BPTH stock opened at $0.81 on Wednesday. Bio-Path has a one year low of $0.59 and a one year high of $9.99. The firm’s 50 day moving average price is $0.89 and its 200-day moving average price is $1.07.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.